Platelet survival time was measured (autologous labelling with 51chromium) in 68 men with coronary artery disease (CAD). Survival was shortened slightly (3.2 ± 0.04 days; mean ± SEM) as compared to normal (3.7 ± 0.04 days; N = 18; P < 0.001), and 60% had shortened survival (< 3.3 days). Thirty-seven had hyperlipoproteinemia (36 with Type IV and one with Type III) and platelet survival was shortened (3.1 ± 0.10 days) and significantly different from survival of men with normal lipoproteins (3.3 ± 0.12 days; P < 0.05). Twenty-two with shortened platelet survival and CAD received either clofibrate or sulfinpyrazone. Clofibrate prolonged platelet survival (2.6 ± 0.09 to 3.4 ± 0.14 days; P < 0.001) and ten of 12 had prolongation of survival. Sulfinpyrazone increased survival (2.8 ± 0.12 to 3.6 ± 0.21; P < 0.001) and nine of ten had prolongation of platelet survival. THE RELATIONSHIP between thrombosis and atherosclerosis has been investigated for many years.1 Recently, consideration that the interaction between the blood platelet and the arterial endothelium contributes to the pathogenesis of the vascular damage has led to proposals that therapeutic trials of agents which interfere with this interaction might show that the extent and impact of vascular damage could be reduced. 6' 7 In an earlier study we suggested that platelet survival time was frequently shortened in patients with coronary artery disease.8 Eleven of 21 patients (52%) with angiographically confirmed coronary disease had shortened platelet survival.
Platelet survival time was measured (autologous labelling with 51chromium) in 68 men with coronary artery disease (CAD). Survival was shortened slightly (3.2 ± 0.04 days; mean ± SEM) as compared to normal (3.7 ± 0.04 days; N = 18; P < 0.001), and 60% had shortened survival (< 3.3 days). Thirty-seven had hyperlipoproteinemia (36 with Type IV and one with Type III) and platelet survival was shortened (3.1 ± 0.10 days) and significantly different from survival of men with normal lipoproteins (3.3 ± 0.12 days; P < 0.05). Twenty-two with shortened platelet survival and CAD received either clofibrate or sulfinpyrazone. Clofibrate prolonged platelet survival (2.6 ± 0.09 to 3.4 ± 0.14 days; P < 0.001) and ten of 12 had prolongation of survival. Sulfinpyrazone increased survival (2.8 ± 0.12 to 3.6 ± 0.21; P < 0.001) and nine of ten had prolongation of platelet survival. Clofibrate lowered serum cholesterol and tryglyceride but alteration in lipids did not THE RELATIONSHIP between thrombosis and atherosclerosis has been investigated for many years.1 Recently, consideration that the interaction between the blood platelet and the arterial endothelium contributes to the pathogenesis of the vascular damage has led to proposals that therapeutic trials of agents which interfere with this interaction might show that the extent and impact of vascular damage could be reduced. 6' 7 In an earlier study we suggested that platelet survival time was frequently shortened in patients with coronary artery disease.8 Eleven of 21 patients (52%) with angiographically confirmed coronary disease had shortened platelet survival.
Recently, data has been presented which suggests that clofibrate, a lipid-lowering drug, favorably alters mortality in patients with coronary disease,9'1-although some of the conclusions of these studies have been questioned on statistical grounds12 and very recently, the Coronary Drug Project Research Group reported that clofibrate failed to alter mortality in men with coronary disease. 13 Of particular interest in these clinical trials was the finding that the alteration of mortality by clofibrate was not associated with the lowering of serum lipids. This suggested another mechanism for the drug's favorable effect. Gilbert and Mustard have shown that clofibrate prolonged platelet survival time in ten of 11 patients, six of whom probably had coronary disease,14 and recently, Carvalho and associates have demonstrated that clofibrate normalized abnormal platelet sensitivity to aggregating agents in vitro in patients with familial hyperbetalipoproteinemia. 15 The present study was undertaken to determine the frequency of occurrence of shortened platelet survival time in coronary disease and to assess the effect of clofibrate and sulfinpyrazone on shortened platelet survival in these patients.
Patients
Platelet survival time was measured in 68 men (age 29 
Results
Average platelet survival half-time for the 68 men with coronary disease was only slightly shortened at 3.2 + 0.04 days, but significantly different (P < 0.001) from the normal average of 3.7 days ( fig.  1 ). Forty-one of the 68 (60%) had shortened platelet Twenty-two of these men with shortened platelet survival were treated with either clofibrate (2 g/day) or sulfinpyrazone (800 mg/day) for three months and measurement of platelet survival, lipids, and lipoproteins repeated.
Twelve men received clofibrate which significantly (P < 0.001) prolonged average platelet survival time from 2.6 ± 0.09 to 3.4 ± 0.14 days (table 1, fig. 3 ). Ten had prolongation of platelet survival by more than 0.2 days half-time and six became normal (> 3.3 days). Clofibrate had the expected lipid-lowering effect (table 1), but alteration of platelet survival did not correlate with either the initial lipid level or the alteration of lipids.
Ten patients received sulfinpyrazone which significantly (P < 0.001) prolonged average platelet survival time from 2.8 ± 0.12 to 3.6 + 0.21 days (table 2, fig. 4 
